Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Doxorubicin, Etoposide, Prednisolone, Rituximab, and Vincristine in patients with Non-Hodgkin Lymphoma.

View API

Statements

Source and description

View API